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Calcium Sulphate/Hydroxyapatite Carrier for Bone
Formation in the Femoral Neck of Osteoporotic Rats
Aurimas Sˇirka, MD,1,2,* Deepak Bushan Raina, BE,2,* Hanna Isaksson, PhD,2,3 K. Elizabeth Tanner, PhD,2,4
Alfredas Smailys, MD, PhD,1 Ashok Kumar, PhD,5 Sˇarunas Tarasevicˇius, MD, PhD,1
Magnus Ta¨gil, MD, PhD,2 and Lars Lidgren, MD, PhD2
This study investigated bone regeneration in the femoral neck canal of osteoporotic rats using a novel animal
model. A calcium sulphate (CS)/hydroxyapatite (HA) carrier was used to deliver a bisphosphonate, zoledronic
acid (ZA), locally, with or without added recombinant human bone morphogenic protein-2 (rhBMP-2). Twenty-
eight-week-old ovariectomized Sprague–Dawley rats were used. A 1 mm diameter and 8 mm long defect was
created in the femoral neck by drilling from the lateral cortex in the axis of the femoral neck, leaving the
surrounding cortex intact. Three treatment groups and one control group were used: (1) CS/HA alone, (2) CS/
HA + ZA (10mg) (3) CS/HA + ZA (10mg) + rhBMP-2 (4mg), and (4) empty defect (control). The bone formation
was assessed at 4 weeks post surgery using in vivo micro computed tomography (micro-CT). At 8 weeks post
surgery, the animals were sacrificed, and both defect and contralateral femurs were subjected to micro-CT,
mechanical testing, and histology. Micro-CT results showed that the combination of CS/HA with ZA or ZA +
rhBMP-2 increased the bone formation in the defect when compared to the other groups and to the contralateral
hips. Evidence of new dense bone formation in CS/HA + ZA and CS/HA + ZA + rhBMP-2 groups was seen
histologically. Mechanical testing results showed no differences in the load to fracture between the treatments
in either of the treated or contralateral legs. The CS/HA biomaterial can be used as a carrier for ZA and rhBMP-
2 to regenerate bone in the femoral neck canal of osteoporotic rats.
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Introduction
Osteoporosis and fragility fractures are increasingwith the increase in age and are only partly halted by
primary and secondary national prevention programs.1 More
than 8.9 million osteoporotic fractures occur annually
worldwide, with approximately one-third in Europe.2 The
direct cost of managing osteoporosis was estimated at e37
billion, but if quality-adjusted life-years lost were consid-
ered, the overall cost amounted to e98 billion in Europe in
2010.2 Due to the aging population, fragility fractures are
predicted to increase further in the next decade.2 The life
expectancy in hip fracture patients decreases by nearly 25%
when compared to age- and sex-matched populations.3 One
fifth of all fragility fractures occur in the hip, with an almost
equal ratio in the cervical and trochanteric region.2
Primary and secondary prevention methods evaluated for
osteoporosis include calcium and vitamin D supplements,
bisphosphonates, parathyroid hormone and its analogues,
and biological drugs targeting resorption (Denosumab, anti-
RANKL).4 Zoledronic acid (ZA) is a bisphosphonate and
has been shown to reduce the risk of hip fracture by 41% in
postmenopausal women.5 However, systemic usage of ZA is
reported to have side effects, including myalgia6 and os-
teonecrosis of the jaw, with prolonged use.7 The interest in
osteoporosis therapy is declining, in particular for secondary
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fracture prevention where the risk of subsequent hip frac-
tures following a first fracture is high.8 This is to some
extent based on reports of long-term adverse effects with
systemic bisphosphonates causing atypical fractures and
lack of patient adherence to taking bisphosphonates, with
half of patients stopping treatment during the first year.9
Thus, there is a need for novel preventive treatment mo-
dalities, especially as major osteoporotic fractures per se are
linked to increased mortality.3
Bone morphogenic protein-2 (BMP-2) induces osteogenic
differentiation of mesenchymal cells and preosteoblasts into
mature osteoblasts.10,11 Several studies have indicated that
sustained and controlled release of BMP-2 over a longer
period of time is required for optimal bone regeneration.12
The currently approved carriers for local delivery of re-
combinant human BMP-2 (rhBMP-2) provide only a burst
release.13 Moreover, rhBMP-2 induces premature bone re-
sorption by also stimulating osteoclasts,14,15 which in turn
can be controlled by co-delivery of ZA.11,16,17 To investi-
gate this approach, the authors developed an injectable
calcium sulphate/hydroxyapatite (CS/HA) based biomate-
rial, which has been approved for clinical use in Europe.18,19
The powder phase of the CS/HA biomaterial is premixed at
a ratio of 60:40 (CS:HA) by weight. The powder is mixed
with a liquid phase consisting of an iodine-based contrast
agent to allow radiographic visualization. After mixing with
an aqueous solution, the CS hemi-hydrate particles change
state to the dihydrate, causing the biomaterial to set into a hard
mass, wherein HA particles are embedded in the composite
material. The CS phase dissolves in less than 2 months,20
leaving behind a porous osteoconductive matrix of HA as a
scaffold for bone cells to grow on. In a previous study, local
co-delivery of rhBMP-2 and ZA using the CS/HA biomaterial
as carrier led to a significant increase in bone formation in an
abdominal muscle pouch model when compared to BMP-2-
only group.16 Other studies have shown that when ZA was
added to the carrier in a tibia defect model in rats, more newly
formed bone remained within the defect compared to when
the material was used alone.21,22
This study created a novel animal model to investigate the
process of bone regeneration in the femoral neck canal in
osteoporotic rats. Second, the study investigated whether a
CS/HA carrier delivering ZA or a combination of ZA and
rhBMP-2 can improve bone regeneration in the femoral neck
of osteoporotic rats with the long-term goal of preventing
future osteoporotic fractures. It was hypothesized that (1) HA
would provide an osteoconductive scaffold for bone formation
and controlled delivery of both rhBMP-2 and ZA by inter-
acting with them; (2) the fast resorbing CS would increase
scaffold osteoconductivity and provide release of unbound
rhBMP-2 and ZA; (3) rhBMP-2 would lead to differentia-
tion and proliferation of progenitor cells; and (4) ZA could
counteract premature bone resorption, leading to increased
net bone formation.
Methods
Sample preparation and experimental groups
Animals were randomly allocated to the following groups
(n = 12/group): (1) CS/HA (CS/HA in the ratio of 60:40 w/w),
(2) CS/HA + ZA (10mg), (3) CS/HA + ZA (10mg) + rhBMP-
2 (4mg), and (4) empty defect (drilled but no filling). For the
CS/HA group, the ceramic components were mixed without
the addition of any bone active molecules. All animals with
CS/HA treatment received 116 mg of the CS/HA powder, and
the liquid-to-powder ratio remained unchanged (0.43 mL–1 g
powder). The addition of ZA and rhBMP-2 was performed by
adding a known amount of ZA solution or the combination of
ZA and rhBMP-2 solution to the ceramic powder, followed
by rigorous mixing. The doses of rhBMP-2 and ZA were
chosen based on a previous study using the CS/HA bioma-
terial.22 After mixing, the material was transferred into a 1 mL
graded syringe. Equal portions of the sterile paste were de-
livered onto a sterile dish, and each portion was impacted into
one animal, thereby controlling the amount of the CS/HA
biomaterial and respective drugs. The biomaterial was allowed
to reach a suitable viscosity for impaction before implantation
to allow for complete filling of the defect without any back-
flow of the material.
Animal model and surgical procedure
Ovariectomized (OVX) female Sprague–Dawley rats of 28
weeks age at surgery with an average weight of 442– 29 g
were used. OVX was performed at 12 weeks of age (Janvier
Labs, Le Genest-Saint-Isle, France). The animals were left for
16 weeks to develop osteoporosis based on a previous
study.23 Animals were anesthetized using an intraperitoneal
injection of ketamine (90 mg/kg; Apoteket AB, Karlstad,
Sweden) and xylazine (9 mg/kg; Apoteket AB). An intra-
muscular injection of antibiotic solution (Streptocillin Vet;
Apoteket AB) was also given before surgery. The right leg
was shaved and disinfected, and a 1.5 cm straight postero-
lateral incision was made along the greater trochanter. The
muscles were bluntly dissected and the leg internally rotated
until the posterior short rotators were exposed. Tenotomy of
the short rotators was performed, and the posterior capsule
was reached for visualization but left intact. A 1 mm drill was
used to create a critical defect in the femoral neck canal
without fluoroscopic guidance, with the entry point behind
the crest of the greater trochanter toward the superior-lateral
part of the femoral head (Fig. 1). Drilling was stopped at the
base of the sub-capital zone, producing a defect depth of
approximately 8 mm (Fig. 1). At this point, the material based
on each treatment group mentioned above was impacted into
the femoral canal using a 1 mm mandrel until the whole canal
was filled with the material. Filling was made in a similar
fashion in all animals. The left leg was left intact and used as
a paired control. After wound closure, a single subcutaneous
injection of buprenorphine (0.04 mg/kg; Temegesic; Apo-
teket AB) was given post surgery for pain control.
To establish the degree of osteoporosis, another three
SHAM-operated and four OVX animals were used as con-
trols, with no defect created in the femoral neck canal. SHAM
animals underwent a bilateral skin incision in the lower ab-
domen at the age of 12 weeks, but no OVX were made. The
OVX animals had their ovaries removed at 12 weeks. The
animals (three SHAM and four OVX) were sacrificed at the
same time as the experimental animals. The proximal tibiae
were subjected to micro computed tomography (micro-CT),
and trabecular bone analysis was performed *1.5 mm distal
to the tibial growth plate, with a region of interest (ROI)
extending 150 slices distally (2.25 mm in total).
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In vivo micro-CT at 4 weeks
The animals were anesthetized using a mixture of isoflurane
(4%), oxygen, and nitrous oxide at a flow rate of 0.4 L/min.
Once asleep, the animals were moved to an animal holder of
the micro-CT scanner (NanoScan; Mediso Medical Imaging
Systems, Budapest, Hungary), and the isoflurane was reduced
to 2%. Circular micro-CT scans were taken with 480 projec-
tions and medium zoom at 65 kV voltage and 1300 ms expo-
sure time, and the images were post-reconstructed to a voxel
size of 20mm. Micro-CT imaging at the 4-week time point was
performed only on the defect side.
Sacrifice and femur harvesting at 8 weeks
The animals were sacrificed using carbon dioxide asphyx-
iation 8 weeks post surgery. Both femurs (defect side and
contralateral) were harvested, wrapped in saline soaked gauze,
and placed in 5 mL Eppendorf tubes. All analyses were per-
formed on both the defect and contralateral legs. Freshly
harvested specimens were subjected to micro-CT and there-
after frozen at -20C until biomechanical testing.
Ex vivo micro-CT at 8 weeks
The samples in the CS/HA group (n = 11) and the other
groups (n = 12) were scanned at an operating voltage of
65 kV, exposure time of 1300 ms, maximum zoom, with 480
projections in circular scan mode using a NanoScan micro-
CT scanner (Mediso Medical Imaging Systems). The im-
ages were post-reconstructed to a voxel size of 10 mm.
Micro-CT image processing and analysis
All images from the 4- and 8-week time points were
analyzed according to the same protocol. Images were post-
reconstructed using Nucline software (inviCRO, Boston,
MA) using a RAMLAK filter with a 100% cut-off. Images
were realigned using Data Viewer (v.4; Skyscan, Kontich,
Belgium) to obtain a straight rectangular defect in the sag-
ittal and coronal views. Trans-axial slices revealed a circular
defect starting from the base of the sub-capital zone down to
the point of entry in the femur. The analysis was performed
on the trans-axial slices using CTAn v1.9.1.0 (Skyscan) and
two different ROIs were used (Fig. 2). In both ROI 1 and
ROI 2, the diameter of the ROI was 1 mm, corresponding to
the diameter of the drill bit. ROI 1 contained the entire
defect, starting at the base of the sub-capital zone to the
point of entry in the posterior cortex. The defect depth was
5 mm, which is less than the original defect, to exclude the
cortical bone at the point of entry and any remaining old
trabecular bone near the sub-capital zone. ROI 2 contained
only the femoral neck canal region, which started at the base
of the sub-capital zone to the end of the femoral neck canal
(depth 3.4 mm). Images were thresholded using a lower gray
scale value of 90 and an upper gray scale value of 255. This
means that both bone and some remnants of the CS/HA
material were identified as mineralized tissue. Mineralized
FIG. 1. Surgical procedure. (A) The exposed site of incision. (B) The bone being drilled at the crest of the femur using a
posterior approach with the drill bit used to create the defect (inset). (C) The position of the drill bit after completion of the
drilling, and the black arrow points at the femoral head. (D) The point of entry in the cortical bone. (E) A piece of CS/HA
biomaterial (black arrow) being impacted into the defect using a mandrel. Inset in (E) shows the mandrel used for
impaction. CS, calcium sulphate; HA, hydroxyapatite. Color images available online at www.liebertpub.com/tea
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volume/tissue volume (MV/TV%) was used as the primary
outcome variable of the micro-CT analysis. The in vivo and
ex vivo scans were performed using different imaging pro-
tocols, which were optimized for each condition. Thus, a
direct comparison of MV/TV% at 4 and 8 weeks was not
possible.
Ex vivo biomechanical testing of the femoral neck
The bones were thawed at room temperature before per-
forming the biomechanical testing, and care was taken to
keep the samples moist until testing. All bone samples for
mechanical testing (n = 9/group) were cut at the mid-
diaphysis to ensure a stable grip during the testing. The bone
specimen was kept in position using a cylindrical holding
device mounted on an adjustable stage to achieve a femoral
shaft angle of 9, with the vertical plane as described by
Hessle et al.24 Using a mechanical testing machine (In-
stron 8511.20 biaxial load frame connected to a MTS
FlexTest 40 Controller, MTS TestSuite Multipurpose Elite
Software) and a 250 N load cell, the femoral head was
loaded using a flat-end indentation device at a displacement
rate of 1 mm/s until the fracture occurred. The experimental
setup is shown in Supplementary Figure S1 (Supplementary
Data are available online at www.liebertpub.com/tea). The
peak load to fracture was recorded for each specimen and
compared between the groups as well as to the contralateral
side. Moreover, the ratio of the peak force between the
defect leg and contralateral leg was calculated. The location
of the fracture site (lateral vs. sub-capital) was also noted.
Qualitative histology
Bone specimens (n = 2/group) that were not mechanically
tested were thawed to room temperature and fixed in
neutral-buffered formalin overnight followed by decalcifi-
cation using ethylenediaminetetraacetic acid (10% w/v, pH
7.2) for 4 weeks. Post decalcification, specimens were de-
hydrated and infiltrated with paraffin overnight. Finally, the
specimens were embedded in paraffin and cooled at 4C
overnight before sectioning. All specimens were cut using a
microtome (Thermo Fisher Scientific, Waltham, MA) to a
thickness of 5 mm. Slides were deparaffinized, rehydrated,
and stained with hematoxylin and eosin using standard
staining techniques. The stained slides were scanned on a
high-resolution slide scanner (Hamamatsu Photonics, Ha-
mamatsu, Japan) before analysis.
Animal ethics statement
All animal experimentation was approved by the Swedish
Board of Agriculture (animal ethics permit no. M 128-16).
Animals had free access to food pellets and drinking water.
Statistics
IBM SPSS Statistics for MacOS v24 (IBM Corp., Armonk,
NY) was used for statistical analysis. Distribution of data was
tested using the Shapiro–Wilk test (on residues) and by
looking at the spread of the data. Normally distributed data
were tested using analysis of variance (ANOVA). Homo-
geneity of variances were tested using Levene’s test, and in
FIG. 2. Micro-CT ROI selection
for quantification. Top panel shows
the dimensions used for micro-CT
analysis in ROI 1, while the bottom
panel shows the dimensions used
for ROI 2. The above image is only
for representation and belongs to
the empty group. Micro-CT, micro
computed tomography; ROI,
region of interest. Color images
available online at www
.liebertpub.com/tea
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the case of nonhomogeneous variances, ANOVA with Games
Howell post hoc test was used, while homogenous variance
data sets were analyzed using ANOVA with Tukey’s HSD
post hoc test. Non-normally distributed data were analyzed
using an independent samples Kruskal–Wallis test for multiple
groups. All paired analysis was performed using Wilcoxon’s
signed rank test.
Results
Microstructural analysis of the bone in the proximal tibial
metaphysis comparing unoperated SHAM versus OVX ani-
mals confirmed significant bone loss in the OVX animals
(Supplementary Table S1). Postoperative radiographs showed
no complications in any of the animals. One animal in the CS/
HA group died at the 4-week micro-CT imagining session due
to anesthesia complication. One sample from the CS/HA + ZA
group was excluded from the 4-week micro-CT analysis due to
movement artifacts during the in vivo scans. During the 8-week
micro-CT analysis, one sample each from the empty group and
the CS/HA + ZA group were excluded due to artifacts during
imaging. Initially, n=9/group were used for mechanical testing,
but one sample in each of the empty, CS/HA, and CS/HA + ZA
+ rhBMP-2 groups had to be excluded due to fractures occur-
ring in the femoral neck canal during the adjustment of the
compression device. Thus, the sample sizes for the biome-
chanical testing were n=8 for the empty, CS/HA, and CS/HA
+ ZA + rhBMP-2 groups and n=9 for the CS/HA + ZA group.
In vivo micro-CT at 4 weeks
In ROI 1, that is, the entire drilled region, the MV/TV in
all CS/HA-treated groups was higher than in the empty
group ( p < 0.001; Fig. 3A). The MV/TV in the CS/HA + ZA
group was also higher than in the CS/HA group ( p < 0.01).
No differences were seen in the MV/TV between the CS/HA
and CS/HA + ZA + rhBMP-2 groups. Furthermore, no dif-
ferences were observed between the CS/HA + ZA and CS/
HA + ZA + rhBMP-2 group. Similar results were seen in
ROI 2 (femoral neck canal), with the only difference being
that the CS/HA + ZA + rhBMP-2 group was higher than the
CS/HA group (Fig. 3B; p < 0.05).
Ex vivo micro-CT at 8 weeks
For ROI 1, the MV/TV was higher in the CS/HA group
( p < 0.05) and in the CS/HA + ZA and CS/HA + ZA +
rhBMP-2 groups ( p < 0.001) compared to the empty group
(Fig. 4A). Both the CS/HA + ZA group and the CS/HA +
ZA + rhBMP-2 group had significantly higher MV/TV com-
pared to the CS/HA group ( p < 0.001). No significant dif-
ferences were seen between the CS/HA + ZA and CS/HA +
ZA + rhBMP-2 groups. In ROI 2, no differences were seen
in MV/TV between the empty group and the CS/HA group
(Fig. 4B). The MV/TV in both the CS/HA + ZA and the
CS/HA + ZA + rhBMP-2 groups was higher than both in the
empty group and the CS/HA group ( p < 0.001). Similar to
ROI 1, no significant differences in the MV/TV% was seen
between the CS/HA + ZA group and the CS/HA + ZA +
rhBMP-2 group.
Irrespective of the treatment on the defect side, no sig-
nificant differences in MV/TV was seen in the contralateral
leg in ROI 1 or ROI 2 (Table 1).
When comparing the defect leg to the contralateral leg,
the MV/TV in both ROI 1 and ROI 2 was significantly lower
in the defect leg of the empty group ( p < 0.05; Table 1). No
changes in the MV/TV in either ROI 1 or ROI 2 was seen
between the defect and the contralateral legs when CS/HA
was implanted (Table 1). The MV/TV of the CS/HA + ZA
group and the CS/HA + ZA + rhBMP-2 group in the defect
leg was higher than their respective contralateral legs
( p< 0.01) for both ROI 1 and ROI 2 (Table 1).
Ex vivo biomechanical testing of the femoral neck
No difference was found in the peak force to fracture in
the biomechanical testing for either the defect or contralat-
eral control legs (Fig. 5). However, when a paired analysis
between the defect and contralateral controls was per-
formed, the defect leg in the CS/HA group had significantly
lower average peak force to fracture ( p < 0.05; Table 1). In
all other groups, no significant differences in the peak force
to fracture between defect and contralateral legs could be
observed (Table 1).
Location of fracture
Fractures were classified as lateral or sub-capital, and a
description of fracture location for each treatment group is
provided in Figure 6.
Qualitative histology
The empty group showed no signs of bone formation in
the defect region, that is, neither in the femoral neck canal
region nor in the femoral region (Fig. 7A–C). In the CS/HA-
treated group (Fig. 7D–F), small amounts of new bone could
be seen in the femoral neck canal (Fig. 7E). However, it
was noted that the material had migrated toward the femo-
ral region, as seen by HA crystals in the medullary canal
(Fig. 7F). Signs of new bone formation were more pro-
nounced in this region. In both the CS/HA + ZA (Fig. 7G–I)
and CS/HA + ZA + rhBMP-2 (Fig. 7J–L) groups, more new
bone could be seen both in the femoral neck canal and to-
ward the femoral region. In many areas, bone could be seen
growing around the HA particles. Furthermore, remnants of
the material could also be seen in both cases. The bone
formed in the CS/HA + ZA + rhBMP-2 group appeared to
be more remodeled, characterized by the presence of more
remodeled and less compact trabecular islands throughout
the defect area. Contrary to this, the bone formed in the CS/
HA + ZA groups was more densely organized.
Discussion
This study evaluated bone formation in a novel femoral
neck model of bone regeneration following implantation of
an injectable bio ceramic using OVX rats to mimic post-
menopausal osteoporosis. In osteoporosis, the femoral neck
is of the highest clinical interest for local bone augmentation
and fracture prevention. Several studies have demonstrated
the effect of OVX on bone loss at various anatomical sites
in rats.23,25,26 The Food and Drug Administration has also
approved the OVX rat model as a model to study both
pharmacological and material testing for osteoporosis. The
strain, age at OVX and age at surgery, affecting trabecular
bone loss, were chosen based on a previously published
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study by Li et al. who performed OVX on 3-month-old
Sprague–Dawley rats. A significant reduction in the amount
of trabecular bone was reported 90 days post OVX, reaching
a plateau at approximately 9 months post OVX.23 The effect
of OVX on the cortical bone was first noted only 1 year post
OVX. The surgical protocol described in this study has not
been used before in OVX rats. However, a similar model has
been reported earlier in an osteoporotic model of cynomolgus
monkeys.27 Seeherman et al. injected calcium phosphate
biomaterial intraosseously with or without rhBMP-2 (0.75 mg/
animal) into the femoral neck of OVX monkeys and dem-
onstrated an increase in trabecular volume, cortical thickness,
as well as the maximum bending force in the femoral neck 6
months post operation, the maximum duration of their study.27
In vivo micro-CT results at 4 weeks showed a significant
increase in the MV/TV of all CS/HA-treated groups when
compared to the empty group. However, the intergroup
differences in the CS/HA treatment, irrespective of the
bioactive factor added, were less than the differences at 8
weeks, which could be attributed to the high density of the
biomaterial, interfering with the micro-CT quantifications at
4 weeks. An earlier study of the degradation of the CS/HA
biomaterial in an ectopic muscle pouch model showed that
the CS phase takes around 6 weeks to resorb, while the
HA remained through the 8 weeks of the study.20 This slow
degradation of the material during the initial 4 weeks might
explain the small differences between the MV/TV in all the
CS/HA-treated groups at 4 weeks. At 8 weeks, when all CS
phase has been resorbed, the difference in the MV/TV in the
CS/HA groups increased. The addition of CS/HA in the defect
led to a significant increase in MV/TV% in ROI 1 compared
to the empty group ( p< 0.05). The choice of augmenting the
CS/HA biomaterial with rhBMP-2 and ZA was obvious due to
osteoinductive properties of rhBMP-2 and anti-resorptive
properties of ZA. Both molecules have been extensively used
in preclinical models mimicking osteoporosis.28–30 Mathavan
et al. recently showed that when using BMP-7 in an osteo-
porotic rat femoral osteotomy model, a 100% union rate was
FIG. 3. Micro-CT results from 4 weeks post surgery. (A and B) The MV/TV% in ROI 1 and ROI 2, respectively, from the
in vivo scans at 4 weeks post surgery. *p < 0.05, **p < 0.01, and ***p< 0.001. Color images available online at
www.liebertpub.com/tea
FIG. 4. Micro-CT results from 8 weeks post surgery. (A and B) The MV/TV% of the defect leg in ROI 1 and ROI 2,
respectively, 8 weeks post surgery. *p < 0.05, and ***p < 0.001. Color images available online at www.liebertpub.com/tea
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achieved compared to 56% in untreated control rats. This
study also demonstrated a slightly increased effect of BMP-7
in osteoporotic animals compared to the nonosteoporotic
rats.29 Similarly, Gao et al. used a HA-coated titanium implant
with a surface coating of ZA in the tibiae of OVX rats. They
found that around an eight times higher pushout force was
required for implants in the ZA-treated group compared to the
untreated group.30
The results from the 8-week micro-CT experiments cor-
roborate well with the published results. The addition of
rhBMP-2 and ZA increased MV/TV in both defect ROIs
significantly compared to the empty and the CS/HA group
alone. Also, noteworthy is that the micro-CT results between
the CS/HA + ZA and the CS/HA + ZA + rhBMP-2 groups did
not show any significant differences. This suggests that con-
trolled and local delivery of ZA alone in a bony environment
may lead to significant bone formation. This is a debatable
finding, and while some in vitro studies have suggested ZA at
very low concentrations can induce osteogenic differentiation
of mesenchymal stem cells,31 others described ZA-inducing
FIG. 5. Biomechanical analysis 8 weeks post surgery. (A and B) The peak force to fracture in the defect leg and the
contralateral leg, respectively, 8 weeks post surgery. No statistically significant differences between the groups were found.
Color images available online at www.liebertpub.com/tea
FIG. 6. Biomechanical testing and
location of fracture. Top panel shows
fracture classification based on the
location of the fracture: Arrow in the
left image points to the lateral fracture
and the arrow in the right image
points at the sub-capital fracture.
Table in the bottom panel shows the
number of fractures of each type in
different treatment groups and tested
legs. Color images available online at
www.liebertpub.com/tea
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apoptosis in human osteosarcoma cells, MG-63.32 Recent
studies have shown a positive effect by local delivery of ZA
alone in a bone defect in vivo.21,22,30 Whether these effects are
only anti-catabolic, meaning that ZA prevents resorption of
bone that would form irrespective of treatment with a bioac-
tive molecule or if endogenous growth factors including
BMPs act synergistically with ZA, is unknown. Further
mechanistic studies are required to establish the ability of ZA
to cause increased net bone formation.
An important aspect of this study was to ensure the local
delivery of both ZA and rhBMP-2. The aim was to cir-
cumvent the side effects of systemic administration of ZA
and targeted spatiotemporal delivery of rhBMP-2, respec-
tively. Different polymeric systems have been used for this
task.11,33 However, the noninjectability of these materials
requires invasive surgical methods. The CS/HA biomate-
rial provides an injectable platform for delivery of both
bioactive molecules and with a minimally invasive ap-
proach. The comparisons from the micro-CT and biome-
chanical testing of the contralateral sides clearly indicated
that none of the treatments has a systemic effect on the
contralateral femur, which is a major goal of local delivery.
Furthermore, paired analysis of MV/TV of the CS/HA + ZA
and CS/HA + ZA + rhBMP-2 groups showed a significant
increase in the defect leg compared to the contralateral leg,
which emphasizes the efficacy of local delivery in this
model. One might argue that the MV/TV is not an accurate
measure of bone formation when the bone has been treated
with a radiopaque biomaterial such as CS/HA. However,
representative histology from the CS/HA + ZA and CS/HA +
ZA + rhBMP-2 groups confirmed abundant amounts of re-
generated viable trabecular bone in the femoral neck canal
region as well as in the trochanteric region (Fig. 7), thereby
strengthening the micro-CT quantifications.
FIG. 7. Representative
histology 8 weeks post sur-
gery. H&E-stained specimen
from the empty group at low
magnification (A), in the
femoral neck canal (B), and
in the femoral region (C).
H&E-stained specimens
from the CS/HA (D–F), CS/
HA + ZA (G–I), and CS/HA
+ ZA + rhBMP-2 (J–L)
groups. (D, G, and J) A low-
magnification overview of
the samples. (E, H, and K)
Bone formation in the femo-
ral neck canal. (F, I, and L)
Bone formation in the femo-
ral region. The arrows in (A,
D, G and J) point at the point
of entry of the drill bit in the
cortex. *Bone formation.
#Remnants of the CS/HA
material in the form of HA
particles. ZA, zoledronic
acid; rhBMP, recombinant
human bone morphogenic
protein-2; H&E, hematoxylin
and eosin. Color images
available online at www
.liebertpub.com/tea
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As an indirect translation of significant bone regeneration
in the femoral canal of CS/HA + ZA- and CS/HA + ZA +
rhBMP-2-treated animals, one would also expect an in-
creased mechanical strength. However, the biomechanical
testing did not show significant differences between any of
the treatment groups on either of the legs. A mechanical
testing protocol described earlier by Hessle et al. was used.24
In this study, a critical size trabecular bone defect was
created in the femoral neck.34 It is speculated that most of
the compressive mechanical strength (>90%) of the femoral
neck in humans is provided by the cortical bone, whereas
the trabecular bone contributes <10%.34 The trabecular bone
contributes more to the shear strength, which is not tested
in the current compression testing setup. The femoral neck
and the intertrochanteric region have a larger proportion of
trabecular bone than the subtrochanteric region, and the
trabecular bone is generally weaker than the cortical bone.
Another important aspect to emphasize is the age of the
animals used in this study. Li et al. followed the develop-
ment of osteopenia-like features in the proximal femur of
OVX rats over 1 year and only noticed a significant re-
duction in the cortical width after the 1-year time point.23 In
this study, only 16 weeks passed post OVX, and one can
assume that the progression of cortical thinning at this time
point is negligible compared to the non-OVX rats. Poten-
tially, the biological need to guide cortical regeneration in
an already healthy cortex at this time point is absent from a
bone homeostasis perspective. Whether a longer follow-up
post surgery, older age at OVX, or a different mechanical
testing protocol would change the biomechanical results are
only speculative at the moment, and further experiments
will be required to verify these.
The absence of a systemic ZA group is a limitation of the
study, since such a group could potentially have illuminated
the role of local delivery of ZA in this animal model. Fur-
thermore, CS/HA + rhBMP-2 was also not used without ZA.
However, based on previous experience, the authors were
confident about the efficacy of local ZA delivery using the
CS/HA biomaterial.16,22 These studies also indicated that
the CS/HA biomaterial produces significantly higher vol-
ume of bone when combined with both rhBMP-2 and ZA
compared to only rhBMP-2, and thus the number of ex-
perimental animals was reduced based on the guidelines of
the 3Rs Principle.35 The age of the animals at OVX, as well
as the time to wait post OVX, might be considered to be
rather premature, and other studies have suggested different
ages.23,25,36 The age most likely to induce osteoporosis-like
characteristics in the trabecular bone of the proximal femur
of rats reported earlier was chosen.23 Also, the interest in
this study was in trabecular bone regeneration, and slightly
younger rats would have possessed more responsive stem/
progenitor cells compared to older rats.37 The quantitative
results in this study are based on micro-CT imaging, but it is
important to keep in mind that separating new bone for-
mation and ceramic biomaterial remnants is very challeng-
ing. For this reason, the results present quantifications of
bone/material composite with a high density. Despite this,
the representative histology findings support the micro-CT
findings well. Further, this study failed to show whether the
bioavailability of local ZA and rhBMP-2 is only early on or
prolonged in this model. However, according to an ongoing
study, a strong interaction of ZA with the CS/HA bioma-
terial and a sustained release of rhBMP-2 over a period of 4
weeks in-vivo has been confirmed. Based on these results, it
is speculated that ZA is locally available for a long period of
time, while rhBMP-2 could possibly have been released
completely after 8 weeks.38 It was also not possible to elu-
cidate the mechanism of small amounts of released ZA re-
uptake by surrounding bone or other skeletal sites in this
study, though no significant effects were seen on the contra-
lateral side. 14C Radiolabeled ZA might be able to elucidate a
complete pharmacodynamics of ZA from the CS/HA bioma-
terial when injected in the femoral neck canal. Finally, this
study did not elucidate if the addition of ZA has any impact
on CS/HA resorption for which long-term studies would be
required.
Conclusions
In conclusion, the model developed to study the process
of bone regeneration in the femoral neck canal of OVX
rats in this study is novel and promising for future re-
search. The CS/HA biomaterial combined with ZA or both
rhBMP-2 and ZA led to significantly enhanced bone re-
generation in the femoral neck canal of osteoporotic rats
in this model, as seen from micro-CT and histology. CS/
HA biomaterial alone was superior to the empty group in
the entire defect region. Moreover, these results did not
translate into an increased mechanical strength in the
treated legs compared to the untreated legs. Long-term
studies with increased time post OVX and possibly a new
biomechanical testing protocol are required to establish
whether this combination can be used as a preventive
treatment for osteoporotic fractures.
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